Drug Profile
Research programme: pulmonary hypertension therapeutics - Bayer HealthCare/Ludwig Boltzmann Institute
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bayer HealthCare; Ludwig Boltzmann Institute for Lung Vascular Research
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pulmonary hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Pulmonary-hypertension in Germany (Inhalation, Inhalant)
- 30 Jun 2011 Early research in Pulmonary hypertension in Germany (Inhalation)